Arca
Skip to content
Tools
Tools

Vascular disease

Drug research and approvals for vascular disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 5,900 studies of vascular disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 5,900
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 5,900 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 8

Phase 2 12 of 15

Phase 1 or earlier 10

How its trials ended

1,044 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 222 whose ending is known, 45% met their primary endpoint, 8% missed it and 46% stopped early.

  • Completed, result not reported42240%
  • Ongoing23723%
  • Status unknown16316%
  • Met its primary endpoint10110%
  • Stopped: other or unclear616%
  • Stopped: enrollment or feasibility222%
  • Missed its primary endpoint182%
  • Stopped: sponsor or business decision101%
  • Stopped: lack of efficacy5<1%
  • Stopped: funding5<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jan 22, 2026A prospective, multi-national, randomized, double-blind, crossover study to evaluate the efficacy and safety of gadopiclenol-enhanced mra compared to…Gadopiclenol / GadoterateGuerbetPending
Dec 19, 2022Reexamining her cardiovascular risk - ottawa women's longitudinal cohort study (her crown)Ruby-fillOttawa Heart Institute Research CorporationOngoing
May 2, 2019A multi-center, double-blind, placebo-controlled phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved…MacitentanJohnson & JohnsonPending
Oct 10, 2014Perioperative ischemic evaluation-3 trial: a pilot study (POISE-3)Tranexamic acid/ RosuvastatinHamilton Health Sciences CorporationPending
Feb 28, 2014The assessment of prednisone in remission trialPrednisoneMount Sinai HospitalOngoing
Dec 30, 2013A randomized, double-blind placebo-controlled study to evaluate the effects of colchicine on vascular inflammation as assessed with positron emission…Colchicine /[18F]-fluorodeoxyglucose (18-FDG)Montreal Heart InstituteOngoing
Nov 29, 2013Randomized, double-blind, placebo-controlled, parallel-group study to assess cardiovascular outcomes following treatment with ertugliflozin…Ertugliflozin (MK-8835/PF-04971729)Merck & Co. (MSD)Closed

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Apr 14, 2000FlolanTreatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included…GlaxoSmithKlineApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.